1257044-57-7

Basic information

• Product Name: methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate
• Synonyms: methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate
• CAS NO: 1257044-57-7
• Molecular Formula: C19H20N4O3
• Molecular Weight: 352.3871
• Mol File: 1257044-57-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate(1257044-57-7)
• EPA Substance Registry System: methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate(1257044-57-7)

Safety Data

• Hazardous Substances Data: 1257044-57-7(Hazardous Substances Data)

Usage

Description

Methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate is a complex organic compound that features a methyl ester group attached to a 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate moiety. This molecule is recognized for its potential as a drug candidate, with ongoing research into its pharmacological properties. It is hypothesized to have an affinity for specific receptors within the central nervous system, suggesting that it may be beneficial in the treatment of neurological disorders.

Uses

Used in Pharmaceutical Development:
Methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate is utilized as a potential therapeutic agent for neurological disorders due to its suspected receptor affinity within the central nervous system. Its precise mechanism of action and efficacy are subjects of ongoing research, with the aim of developing new treatments for various neurological conditions.
Used in Research and Development:
In the field of medicinal chemistry, this compound serves as a subject of research to explore its pharmacological profile and potential interactions with biological targets. Understanding its properties can contribute to the advancement of drug discovery and the development of novel therapeutics for neurological diseases.
Further research is essential to fully elucidate the potential uses and effects of methyl 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-1-yl)benzoate, ensuring that its applications are grounded in scientific evidence and aligned with the needs of patients and healthcare providers.

Upstream product

• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 110-85-0 piperazine 
• 106614-28-2 methyl 2,4-difluorobenzoate 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 183208-36-8 5-methoxy-1H-pyrrolo[2,3-b]pyridine 
• 98549-88-3 5-hydroxypyrrolo[2,3-b]pyridine 
• 392-09-6 2-fluoro-4-nitro-benzoic acid methyl ester 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 
• 685514-01-6 1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridin-5-ol 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 858116-66-2 5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine 
• 1235865-75-4 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoic acid methyl ester 

Relevant articles and documents

Potential applications of BPFP1 in Bcl-2 protein quantification, carcinoma cell visualization, cell sorting and early cancer diagnosis

Overexpression of the Bcl-2 protein has emerged as a hallmark of carcinoma cells and can be employed as a biochemical biomarker of these cells. Therefore, some Bcl-2 protein fluorescence probes (BPFPs) were designed for Bcl-2 protein quantification and carcinoma cells labeling. The high Bcl-2 protein binding affinity (Ki a range of concentrations of Bcl-2 protein, BPFP1 exhibited the desired fluorescence properties and its fluorescence intensity is proportional to Bcl-2 protein concentration. Therefore, BPFP1 provides a convenient approach for Bcl-2 protein quantification and we could determine the concentration of Bcl-2 protein based on the BPFP1's fluorescence intensity. Subsequent studies revealed that BPFP1 can fluorescently label carcinoma cells by binding to overexpressed Bcl-2 protein in living cells, and can distinguish carcinoma cells (HL-60 cells and ACHN cells) from normal-tissue cells (HUVECs) according to the different Bcl-2 protein expression levels between carcinoma cells and normal tissue cells. In the present study, BPFP1 represents a new tool for Bcl-2 protein quantification, carcinoma cell visualization and cell sorting. Moreover, BPFP1 can be used in the future for early cancer diagnosis by detecting carcinoma cells in patient tissues.

Preparation method of Venetoclax intermediate

The invention belongs to the field of medicinal chemistry. The invention mainly relates to a preparation method of a Venetoclax intermediate (I) methyl-2-(1H-pyrrole [2, 3-B] pyridine-5-oxy)-4-(piperazine-1-yl) benzoate. The preparation method comprises t

PROCESS FOR THE PREPARATION OF VENETOCLAX

The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of particularly useful salts thereof.